Since the PI3K/AKT/mTOR pathway negatively regulates autophagy, effective renal cancer cell treatment with mTOR inhibitors (such as TEMS) may thus be antagonized by the resulting increased cellular protective autophagy (7, 8). This evidence concerns the gene AKT1 and renal carcinoma.